We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Simple Blood Test Could Reveal Kidney Disease Earlier

By LabMedica International staff writers
Posted on 16 Oct 2025

Kidney disease remains one of the leading causes of premature mortality, affecting 13% of the global population and nearly one-third of intensive care patients who develop acute kidney injury (AKI). More...

Detecting kidney damage early is challenging, as current tests rely on changes in urine output and creatinine levels, which appear hours or even days after injury. Researchers are now developing a simple blood test that can identify kidney damage much earlier, enabling timely intervention and easier ongoing monitoring.

The diagnostic tests are being developed by RMIT University (Melbourne, Australia) in partnership with Nexsen Limited (Sydney, Australia). The collaboration leverages RMIT's established NanoBioSensing platform technology to create point-of-care tests capable of identifying AKI within hours and supporting at-home monitoring of chronic kidney disease (CKD). The tests use patented DNA aptamers designed to detect specific biomarkers linked to structural kidney damage, allowing clinicians to investigate the root cause of injury rather than relying solely on kidney function metrics.

The team's ultrasensitive diagnostic technology aims to detect damage much earlier than current methods, which depend on creatinine accumulation or reduced urine output. Current pathology-based tests can take between six and 24 hours to detect abnormalities, delaying life-saving treatment. By targeting biomarkers associated with different kidney structures, the new test is designed to provide a direct measure of tissue injury, offering a faster, more reliable diagnostic tool for healthcare professionals in critical care settings.

In addition to hospital use, the technology aims to empower patients with chronic kidney disease to manage their condition at home, much like blood glucose monitoring for diabetics. The innovation could improve outcomes for more than 850 million people living with kidney conditions worldwide by preventing AKI from developing into irreversible CKD. RMIT and Nexsen are also applying the same biosensing platform to other diagnostics, such as Group B Streptococcus (GBS) testing in pregnant women, demonstrating its versatility for global healthcare applications.

“A new test that can directly investigate the damage to different parts of the kidneys will be a real game-changer,” said Professor Shekhar Kumta. “These new blood tests will be able to diagnose the root cause of the acute kidney injury early, which will play an important role in more clearly defining the optimal clinical management plan for patients.”

Related Links:
RMIT University
Nexsen Limited


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Portable Electronic Pipette
Mini 96
Clinical Chemistry System
P780
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.